BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35412649)

  • 1. Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity?
    Shree T
    Br J Haematol; 2022 Jun; 197(6):659-661. PubMed ID: 35412649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
    Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A
    Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
    Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
    Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
    Madelon N; Lauper K; Breville G; Sabater Royo I; Goldstein R; Andrey DO; Grifoni A; Sette A; Kaiser L; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    Clin Infect Dis; 2022 Aug; 75(1):e1037-e1045. PubMed ID: 34791081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
    Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
    Lim HX; Lim J; Jazayeri SD; Poppema S; Poh CL
    Biomed J; 2021 Mar; 44(1):18-30. PubMed ID: 33727051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
    Torres I; Albert E; Giménez E; Alcaraz MJ; Botija P; Amat P; Remigia MJ; Beltrán MJ; Rodado C; Huntley D; Olea B; Navarro D
    Clin Microbiol Infect; 2021 Nov; 27(11):1672-1677. PubMed ID: 34174397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
    Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.